Co‐depletion of the tumour suppressor STK11/Lkb1, in combination with Tp53 and KRas targeting, resulted in the development of both major NSCLC entities, ADC (TTF1+/∆Np63−/KRT5−) and SCC (TTF1−/∆Np63+/KRT5+; Fig 5A–C). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.